<DOC>
	<DOCNO>NCT02672709</DOCNO>
	<brief_summary>This study aim determine effect end-stage renal disease pharmacokinetics , pharmacodynamics , safety , tolerability apixaban . This single-center open-label pharmacological study . Apixaban prescribe dose 2.5 mg twice per day nine day . The concentration drug measure repetitive blood test first eighth day administration ( non-dialysis day ) . The blood test repeat , , dialysis dialysis day . If study show inadequate suboptimal efficacy 2.5 mg dose , repeat 5 mg twice-daily dose .</brief_summary>
	<brief_title>Apixaban Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<criteria>age &gt; 18 year endstage renal disease stable hemodialysis treatment ( 3 weekly session 4 hour ) least 6 month residual kidney function nonvalvular atrial fibrillation age â‰¥80 year Body mass index ( BMI ) &lt; 21 BMI &gt; 40 active bleeding high bleeding risk ( HAS BLED score &gt; 3 ) active malignancy psychiatric disorder decompensated thyroid disorder decompensated heart failure acute myocardial infarctioncerebrovascular accidenthead trauma last 3 month previous history venous thromboembolic disease last 6 month previous history coagulopathy already treat vitamin K antagonist ( VKAs ) novel oral anticoagulant uncorrected rhythm conduction disturbance dual antiplatelet therapy know liver disease elevate transaminase &gt; 2x upper limit normal Hemoglobin &lt; 90 g/l platelet &lt; 100,000 /ml know hypersensitivity apixaban treatment potent inhibitor inducer cytochrome P450 3A4 and/or Pglycoprotein absence effective contraception applicable drug alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Factor Xa Inhibitors</keyword>
	<keyword>Renal Dialysis</keyword>
</DOC>